Author

Ho Keun Park

Institution: SK bioscience Co., Ltd. (South Korea)

Observed institution: SK bioscience Co., Ltd. (South Korea)

ORCID: 0009-0008-7124-9969

Observed ORCID: 0009-0008-7124-9969

OpenAlex ID: A5080331492

Safety and immunogenicity of the Vi-DT typhoid conjugate vaccine in healthy volunteers in Nepal: an observer-blind, active-controlled, randomised, non-inferiority, phase 3 trial

2021 · Ganesh Kumar Rai, Tarun Saluja, et al. · The Lancet Infectious Diseases · 37

Immunogenicity and Safety of a Newly Developed Live Attenuated Varicella Vaccine in Healthy Children: A Multi-National, Randomized, Double-Blinded, Active-Controlled, Phase 3 Study

2023 · Ui Yoon Choi, Ki Hwan Kim, et al. · Vaccines · 14

Immune non-interference and safety study of Vi-DT typhoid conjugate vaccine with a measles, mumps and rubella containing vaccine in 9–15 months old Nepalese infants

2022 · Tarun Saluja, Ganesh Kumar Rai, et al. · Vaccine · 10

Immune persistence after 5 years of vaccination by Vi-DT vaccine among children below 2 years: Result from long-term observational study

2025 · Rejwana Haque Pial, Maria Rosario Capeding, et al. · Vaccine · 2

Immunogenicity and Safety of a Full-Dose Regimen of Cell Culture-Derived Quadrivalent Inactivated Influenza Vaccine in Children Aged 6–35 Months: Results from a Multinational Phase 3 Randomised Controlled Trial

2026 · Yoonsun Yoon, Hye-Kyung Cho, et al. · Vaccines · 1

Longevity of immune-response provided by at least one dose of vi-DT vaccine 5 years after vaccination among healthy Filipino adults and children

2025 · Rejwana Haque Pial, Maria Rosario Capeding, et al. · Vaccine

Works count: 6

Citation count: 64

H-index: 3

I10-index: 3